Novartis AG
NOVN.SWDividend Aristocrat • 27yrsAutomated dividend-safety read-out from payout, leverage, yield, profitability and track record. See the Financials tab for the full per-statement Financial Investigation. Educational only — not investment advice.
At a glance
Novartis AG (NOVN.SW) operates in the Drug Manufacturers - General industry and is based in Switzerland. It pays a quarterly dividend of CHF 3.70 a year, a yield of 2.78% at the current price of CHF 131.48. Novartis has raised its dividend for 27 consecutive years, which makes it a Dividend Aristocrat. Over the last five years the dividend has grown by an average of 3.5% a year. It paid out 87% of its earnings as dividends. 22 analysts cover it; their average 12-month price target of CHF 129.74 is 1.3% below the current price.
Written automatically from the figures on this page, as of Nov 19, 2026. Facts only, not a recommendation.
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.
Business description from Yahoo Finance. Verify details in the company's own annual report.
Key Metrics
Valuation
Profitability
Financial Health
Data provided by Yahoo Finance via yfinance. Updated daily. Not investment advice.